Olav
Dahl
Professor
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 20 18
E-mail:
Books
- 2009. Medikamentell kreftbehandling. 495 pages. ISBN: 978-829923312-5.
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 495 pages. ISBN: 978-829923312-5.
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 495 pages. ISBN: 978-82-992331-2-5.
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 7. utgave. 495 pages. ISBN: 978-82-9923312-5.
Journal articles
- 2014. J. Krohn og medarbeidere svarer. Tidsskrift for Den norske legeforening. 134: 814. doi: 10.4045/tidsskr.14.0466
- 2014. Brachytherapy for malignant uveal melanoma. Tidsskrift for Den norske legeforening. 134: 529-529. doi: doi: 10.4045/tidsskr.13.1206
- 2013. Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. Human Reproduction. 28: 1995-2002. doi: 10.1093/humrep/det127
- 2013. Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors. Acta Oncologica. 52: 736-744. doi: 10.3109/0284186X.2013.770599
- 2013. Faecal incontinence after chemoradiotherapy in anal cancer survivors: Long-term results of a national cohort. Radiotherapy and Oncology. 108: 55-60. doi: 10.1016/j.radonc.2013.05.037
- 2013. Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in the tumor suppressor gene SPRY4. Norsk Epidemiologi, Supplement. 23: 44-44.
- 2013. Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4. Human Molecular Genetics. 22: 3373-3380. doi: 10.1093/hmg/ddt188
- 2012. Chemoradiotherapy of Anal Carcinoma: Survival and Recurrence in an Unselected National Cohort. International Journal of Radiation Oncology, Biology, Physics. 83: E173-E180. doi: 10.1016/j.ijrobp.2011.12.062
- 2012. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. British Journal of Cancer. 107: 1833-1839. doi: 10.1038/bjc.2012.471
- 2012. Testicular germ cell tumours - still many challenges. Acta Oncologica. 51: 147-150. doi: 10.3109/0284186X.2011.653441
- 2012. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncologica. 51: 168-176. doi: 10.3109/0284186X.2011.641507
- 2012. Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Human Reproduction. 27: 1525-1535. doi: 10.1093/humrep/des075
- 2012. Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. British Journal of Cancer. 106: 756-762. doi: 10.1038/bjc.2011.548
- 2012. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 107: 1684-1691. doi: 10.1038/bjc.2012.463
- 2012. Fibroblast growth factor 2—A predictor of outcome for patients irradiated for stage II-III non–small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 82: 442-447. doi: 10.1016/j.ijrobp.2010.08.048
- 2012. The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer. 118: 157-163. doi: 10.1002/cncr.26282
- 2012. Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma. Journal of Clinical Oncology. 30. 1 pages.
- 2012. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. Journal of Clinical Oncology. 30: 1755-1762. doi: 10.1200/JCO.2011.38.0915
- 2012. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update. International Journal of Hyperthermia. 28: 549-553. doi: 10.3109/02656736.2012.673047
- 2011. Faglige anbefalinger for behandling ved analcancer. StrålevernRapport. 5: 1-34.
- 2011. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS ONE. 6. 13 pages. doi: 10.1371/journal.pone.0026358
- 2011. MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. British Journal of Cancer. 105: 1719-1725. doi: 10.1038/bjc.2011.457
- 2011. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian testicular cancer group. Journal of Clinical Oncology. 29: 2032-2039. doi: 10.1200/JCO.2010.29.1278
- 2011. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 80: 499-505. doi: 10.1016/j.ijrobp.2010.02.003
- 2011. Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group. Journal of Clinical Oncology. 29: 719-725. doi: 10.1200/JCO.2010.30.1044
- 2010. Late side effects and quality of life after radiotherapy for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 76: 1005-1011. doi: 10.1016/j.ijrobp.2009.03.010
- 2010. Late side effects and quality of life after radiotherapy for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 76: 1005-1011. doi: 10.1016/j.ijrobp.2009.03.010
- 2010. Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy. European Urology. 58: 134-140. doi: 10.1016/j.eururo.2010.03.041
- 2010. A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. Journal of cancer survivorship. 4: 256-265. doi: 10.1007/s11764-010-0133-y
- 2010. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. Journal of Clinical Oncology. 28: 4649-4657. doi: 10.1200/JCO.2010.29.9362
- 2010. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. Cancer Detection and Prevention. 34: 359-367. doi: 10.1016/j.canep.2010.04.017
- 2010. Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response. Cancer Research. 70: 8802-8811. doi: 10.1158/0008-5472.CAN-10-0312
- 2010. Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC). Strahlentherapie und Onkologie (Print). 186: 307-314. doi: 10.1007/s00066-010-2131-4
- 2010. A study of coping in long-term testicular cancer survivors. Psychology, Health & Medicine. 15: 146-158. doi: 10.1080/13548501003623955
- 2010. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Annals of Oncology. 21: 1858-1863. doi: 10.1093/annonc/mdq026
- 2009. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics. 41: 1238-1242. doi: 10.1038/ng.465
- 2009. Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. International Journal of Hyperthermia. 25: 41-46. doi: 10.1080/02656730802397955
- 2009. cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 75: 1562-1569. doi: 10.1016/j.ijrobp.2009.08.007
- 2009. Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. 101: 1682-1695. doi: 10.1093/jnci/djp413
- 2009. Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. 101: 1682-1695.
- 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 625: 6-22. doi: 10.1016/j.ejphar.2009.10.009
- 2009. Follow up your unexpected clinical observations! Acta Oncologica. 48: 325-327. doi: 10.1080/02841860902740915
- 2009. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica. 48: 368-376. doi: 10.1080/02841860902755244
- 2009. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 101: 1282-1289. doi: 10.1038/sj.bjc.6605333
- 2009. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncologica. 48: 842-849. doi: 10.1080/02841860902795232
- 2009. Pulmonary Function in Long-Term Survivors of Testicular Cancer. Journal of Clinical Oncology. 27: 2779-2786. doi: 10.1200/JCO.2008.18.5181
- 2009. Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer. European Journal of Cancer. 45: 2383-2390. doi: 10.1016/j.ejca.2009.03.014
- 2009. Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy. Acta Oncologica. 48: 874-881. doi: 10.1080/02841860902974159
- 2009. Topographical distribution of choroidal naevi in the ocular fundus. Eye (London. 1987). 23: 1685-1690. doi: 10.1038/eye.2008.350
- 2009. Topography of solitary congenital hypertrophy of the retinal pigment epithelium in the ocular fundus. ACTA OPHTHALMOLOGICA. 87: 921-922. doi: 10.1111/j.1755-3768.2009.01539.x
- 2009. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. Journal of Clinical Oncology. 27. 2 pages.
- 2009. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicenter randomized trial by The European Society for Hyperthermic Oncology. International Journal of Hyperthermia. 25: 323-334. doi: 10.1080/02656730903091986
- 2009. Rectal cancer with macroscopic peritoneal involvement - clinical challenges and consequences. Colorectal Disease. 11: 838-844. doi: 10.1111/j.1463-1318.2008.01700.x
- 2009. Utilisation of specialist care in patients with incurable rectal cancer. A population-based study from Western Norway. Acta Oncologica. 48: 377-384. doi: 10.1080/02841860802468104
- 2009. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology. 18: 580-588. doi: 10.1002/pon.1437
- 2009. Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program. Journal of Clinical Oncology. 27: 2122-2128. doi: 10.1200/JCO.2008.18.8953
- 2008. Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. International Journal of Hyperthermia. 24: 425-441. doi: 10.1080/02656730802081997
- 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 86: 435-442. doi: 10.1016/j.radonc.2008.01.022
- 2008. Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer. 98: 1264-1273. doi: 10.1038/sj.bjc.6604285
- 2008. 2008 ESHO-BSD award winner - Gerard C. van Rhoon. International Journal of Hyperthermia. 24: 444-445. doi: 10.1080/02656730802383997
- 2008. Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia. 24: 97-110. doi: 10.1080/02656730701824406
- 2008. Analkreft. Tidsskrift for Den norske legeforening. 128: 198-200.
- 2008. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of cancer survivorship. 2: 128-137. doi: 10.1007/s11764-008-0054-1
- 2008. Pulmonary function in long-term testicular cancer survivors. Annals of Oncology. 19: viii205.
- 2008. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of cancer survivorship. 2: 128-137.
- 2008. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. International Journal of Radiation Oncology, Biology, Physics. 70: 1478-1486. doi: 10.1016/j.ijrobp.2007.08.076
- 2008. Incidence of iris melanoma in western Norway. ACTA OPHTHALMOLOGICA. 86: 116-117. doi: 10.1111/j.1600-0420.2007.01011.x
- 2008. Incidence of iris melanoma in western Norway. ACTA OPHTHALMOLOGICA. 86: 116-117. doi: 10.1111/j.1600-0420.2007.01011.x
- 2008. Topographical distribution of posterior uveal melanoma, choroidal nevi, and congenital hypertrophy of the retinal pigment epithelium. ACTA OPHTHALMOLOGICA. 86: 8-8. doi: 10.1111/j.1755-3768.2008.01272.x
- 2008. Posterior uveal melanoma. Distribution of the sites of origin and patterns of tumour extent in the ocular fundus. British Journal of Ophthalmology. 92: 751-756. doi: 10.1136/bjo.2007.133025
- 2008. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. Eye (London. 1987). 22: 1398-1403. doi: 10.1038/sj.eye.6702911
- 2008. Chronic cancer-related fatigue in long-term survivors of testicular cancer. Journal of Psychosomatic Research. 64: 363-371. doi: 10.1016/j.jpsychores.2008.01.002
- 2008. Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncologica. 47: 1257-1264. doi: 10.1080/02841860802244174
- 2008. Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncologica. 47: 1257-1264. doi: 10.1080/02841860802244174
- 2008. Palliative surgery for rectal cancer in a national cohort. Colorectal Disease. 10: 336-343. doi: 10.1111/j.1463-1318.2007.01376.x
- 2008. Rectal cancer with macroscopic peritoneal involvement - clinical challenges and consequences. Colorectal Disease. 23 pages.
- 2008. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology. doi: 10.1002/pon.1437
- 2007. Strålebehandling av endetarmskreft. Tidsskrift for Den norske legeforening. 127: 3090-3093.
- 2007. Is neuroticism associated with long-term morbidity in testicular cancer survivors? Psycho-Oncology. 16.
- 2007. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncologica. 46: 480-489. doi: 10.1080/02841860601166958
- 2007. Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma. Radiotherapy and Oncology. 82: 137-144. doi: 10.1016/j.radonc.2006.11.022
- 2007. Is the sexual function compromised in long-term testicular cancer survivors? European Urology. 52: 1438-1447. doi: 10.1016/j.eururo.2007.02.046
- 2007. Adjuvant kjemoterapi ved tykktarmskreft. Tidsskrift for Den norske legeforening. 127: 3094-3096.
- 2007. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncologica. 46: 639-650. doi: 10.1080/02841860601099241
- 2007. Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin. Scandinavian Journal of Immunology. 65: 192-201. doi: 10.1111/j.1365-3083.2006.01875.x
- 2007. Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology. 18: 241-248. doi: 10.1093/annonc/mdl372
- 2007. Clinical characteristics and outcomes in patients with advanced rectal cancer: A national prospective cohort study. Diseases of the Colon & Rectum. 50: 285-291. doi: 10.1007/s10350-006-0770-4
- 2007. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology. 16.
- 2006. Cardiovascular (CV)morbidity and predicted mortality in long-term testicular cancer (TC) survivors. Annals of Oncology. 17: 443PD.
- 2006. Self-reported paresthesias, Raynaud's phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TG) survivors. Journal of Clinical Oncology. 24: 228S-228S.
- 2006. Self-reported paresthesia, Raynaud,s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. Journal of Clinical Oncology. 24: 228s.
- 2006. Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncologica. 45: 454-462.
- 2006. A concomitant tumour boost in bladder irradiation: Patient suitability and the potential of intensity-modulated radiotherapy. Radiotherapy and Oncology. 80: 98-105. doi: 10.1016/j.radonc.2006.06.015
- 2006. Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology. Published 2006-10-23.
- 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 97: 1580-1588.
- 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 97: 1580-1588.
- 2005. Self-reported paresthesia, Raynaud’s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. European Journal of Cancer. 3.
- 2005. Gonadal hormones, sperm counts and post-treatment paternity in long-term survivors of unilateral testicular cancer. European Journal of Cancer. 3: 228s.
- 2005. Paternity Following Treatment for Testicular Cancer. Journal of the National Cancer Institute. 97: 1580-1588. doi: 10.1093/jnci/dji339
- 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 97: 1580-1588.
- 2005. Study of anxiety disorder and depression in long-term survivors of testicular cancer. Journal of Clinical Oncology. 23: 2389-2395.
- 2005. First things first. Acta Oncologica. 44: 11-12.
- 2005. Clinical hyperthermia combined with radiation is safe. International Journal of Hyperthermia. 21: 193-197.
- 2005. Protons. A step forward or perhaps only more expensive radiation therapy? Acta Oncologica. 44: 798-800.
- 2005. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 44(8): 904-912.
- 2005. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 44: 904-912. doi: 10.1080/02841860500355900
- 2005. SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 17: 485-491. doi: 10.1016/j.clon.2005.04.011
- 2005. Testing the new ICRU 62 'Planning Organ at Risk Volume' concept for the rectum. Radiotherapy and Oncology. 75: 293-302. doi: 10.1016/j.radonc.2005.03.007
- 2005. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. Journal of Clinical Oncology. 23: 3061-3068.
- 2005. Metabolic syndrome in long-term testicular cancer survivors. Journal of Clinical Oncology. 23.
- 2005. Metabolic syndrome in long-term testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 24.
- 2005. Blood pressure and body mass index in long-term survivors of testicular cancer. Journal of Clinical Oncology. 23: 4980-4990.
- 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Supportive Care in Cancer. 13: 637-646.
- 2005. The assosiation between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men i general population sample. Supportive Care in Cancer. 13: 637-646.
- 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Supportive Care in Cancer. 13: 637-646.
- 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorders in long-term survivors of testicular cancer and men in the general population sample. Supportive Care in Cancer. 13: 637-646. doi: 10.1007/s00520-004-0769-0
- 2004. Working ability and educational level among long-term survivors of teasticular cancer (TCSS) compared to a general population (GenPop). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 23. 1 pages.
- 2004. Updated European core curriculum for radiotherapists (radiation oncologists). Recommended curriculum for the specialist training of medical practitioners in radiotherapy (radiation oncology) within Europe. Radiotherapy and Oncology. 70: 107-113.
- 2004. Post-treatment paternity in testicular cancer survivors. Journal of Clinical Oncology. 22: 388S-388S.
- 2004. Post-treatment paternity in testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 23. 1 pages.
- 2004. Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurologica Scandinavica. 109: 378-384.
- 2004. Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 124: 1919-1922.
- 2004. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiotherapy and Oncology. 71: 43-53.
- 2004. Evaluation of a new method for calculation of cumulative doses in the rectum wall using repeat CT scans. Acta Oncologica. 43: 388-395.
- 2004. A Monte Carlo study of the impact of the choice of rectum volume definition on estimates of equivalent uniform doses and the volume parameter. Physics in Medicine and Biology. 49: 3341-3352.
- 2004. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: A pilot study of eight stool markers. Scandinavian Journal of Gastroenterology. 39: 1113-1118. doi: 10.1080/00365520410003614
- 2004. On the use of margins for geometrical uncertainties around the rectum in radiotherapy planning. Radiotherapy and Oncology. 70: 11-19.
- 2004. Testing the new ICRU 62 'planning organ at risk volume' concept for the rectum. Radiotherapy and Oncology. 73.
- 2004. Conformal radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 73: 387-398.
- 2004. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 69: 291-304.
- 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 15: 112-112.
- 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 15: 112-112.
- 2004. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 43: 495-498.
- 2004. Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 22: 31-38.
- 2003. Sustained Prothrombotic profile after Hip Replacement Surgery. The Influence of Prolonged Prophylaxis with Dalteparin. Thrombosis and Haemostasis. 1: 971-975.
- 2003. Gonadal hormones in longterm survivors 10 years after treatment for unilateral testicular cancer. European Urology. 44: 322-328.
- 2003. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 42: 741-748.
- 2003. Risk-adapted brief adjuvant chemotherapy in clinical stage I (CSI) nonseminomatous germ cell testicular cancer (NSGCT). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 22. 1 pages.
- 2003. Brachytherapy for prostatic cancer: a systematic review of clinical and cost effectiveness. European Urology. 44: 40-46.
- 2003. Treatment precision and treatment effect in conformal radiotherapy of urinary bladder cancer - preliminary results. Radiotherapy and Oncology. 68: S94-S94.
- 2003. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 69: 291-304.
- 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 44. 7 pages.
- 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 44: 322-328.
- 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 44: 322-328.
- 2003. Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness. European Urology. 44: 40-46.
- 2003. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 21: 4466-4467.
- 2003. Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 42: 827-831.
- 2003. The level of physical activity in long-term surdivors of testicular cancer. European Journal of Cancer. 39. 6 pages.
- 2003. The level of physical activity in long-term survivors of testicular cancer. European Journal of Cancer. 39: 1216-1221.
- 2002. Hyperthermia alone or combined with cisplatin in addition to radiotherapy for advanced uterine cervical cancer. International Journal of Hyperthermia. 18: 25-30.
- 2002. Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. International Journal of Hyperthermia. 18: 141-152.
- 2002. The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Letters. 178: 209-217.
- 2002. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 62: 173-183.
- 2002. Norwegian Oncologists' Expectations of Intensity-modulated Radiotherapy. Acta Oncologica. 41: 562-565.
- 2002. Brakyterapi ved prostatakreft. Tidsskrift for Den norske legeforening. 122: 2795-2798.
- 2001. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. The Lancet. 358: 1291-1304.
- 2001. Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype. International Journal of Radiation Oncology, Biology, Physics. 51: 535-544.
- 2001. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiotherapy and Oncology. 60: 147-154.
- 2001. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology. 61: 313-320.
- 2001. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. International Journal of Radiation Oncology, Biology, Physics. 51: 1159-1166.
- 2001. Partially wedged beams improve radiotherapy treatment of urinary bladder cancer. Radiotherapy and Oncology. 59: 21-30.
- 2001. Can dose-response models predict reliable normal tissue complication probabilities in radical radiotherapy of urinary bladder cancer? The impact of alternative radiation tolerance models and parameters. International Journal of Radiation Oncology, Biology, Physics. 50: 627-637.
- 2001. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 61. 11 pages.
- 2001. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 40: 882-883.
- 2000. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 55: 111-119.
- 2000. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 55: 111-119.
- 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 46: 645-652.
- 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 46: 645-652.
- 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 120: 2274-2278.
- 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 120: 2274-2278.
- 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 120: 2274-2278.
- 2000. Partially wedged fields formed by dynamic collimation. Medical physics (Lancaster). 27: 527-534.
- 2000. Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 25: 93-97.
- 2000. Partially wedged fields formed by dynamic collimation. Medical physics (Lancaster). 27: 527-534.
- 2000. Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 25: 93-97.
Reports and theses
- 2011. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av testikkelkreft. Helsedirektoratet. 109 pages.
- 2007. Kvalitetsregistre over kreftsykdommer. Sosial- og helsedirektoratet. IS-1523, Oslo. 14 pages.
- 2002. Brachyterapy ved prostatakreft. Medisinsk metodevurdering basert på egen litteraturgjennomgang. SMM-rapport. 2. SINTEF, Oslo. 62 pages.
Book sections
- 2010. L2 Legemidler i behandlingen av kreftsykdommer. L2, pages 775-820. In:
- 2010. Norsk legemiddelhåndbok for helsepersonell 2010. 2099 pages. ISBN: 9788290732108.
- 2009. Kreftceller og kjemoterapi. Kapittel 1, pages 13-37. In:
- 2009. Medikamentell kreftbehandling. 495 pages. ISBN: 978-829923312-5.
- 2009. Kreftceller og kjemoterapi. Kap. 1, pages 13-37. In:
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 7. utgave. 495 pages. ISBN: 978-82-9923312-5.
- 2009. Medikamentell kreftbehandling. Kapittel 2, pages 38-45. In:
- 2009. Medikamentell kreftbehandling. 495 pages. ISBN: 978-829923312-5.
- 2009. Medikamentell kreftbehandling. Kap. 2, pages 38-45. In:
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 7. utgave. 495 pages. ISBN: 978-82-9923312-5.
- 2009. Cancer testis. Kap. 31, pages 404-411. In:
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 7. utgave. 495 pages. ISBN: 978-82-9923312-5.
- 2009. Kreft i nyre, ureter, urinblære og prostata. Kap. 30, pages 396-403. In:
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 7. utgave. 495 pages. ISBN: 978-82-9923312-5.
- 2009. Bivirkninger. Kap. 4, pages 56-74. In:
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 7. utgave. 495 pages. ISBN: 978-82-9923312-5.
- 2009. Bivirkninger. Kapittel 4, pages 56-74. In:
- 2009. Medikamentell kreftbehandling. 495 pages. ISBN: 978-829923312-5.
- 2009. Gastrointestinal kreft. Kap. 27, pages 363-375. In:
- 2009. Medikamentell kreftbehandling. Cytostatikaboken. 7. utgave. 495 pages. ISBN: 978-82-9923312-5.
- 2007. Legemidler i behandlingen av kreftsykdommer. Kapittel L2, pages 703-740. In:
- 2007. Norsk legemiddelhåndbok for helsepersonell 2007. 1743 pages. ISBN: 978-82-90732-09-2.
- 2007. Kreftsykdommer. Kapittel T2, pages 93-112. In:
- 2007. Norsk legemiddelhåndbok for helsepersonell 2007. 1743 pages. ISBN: 978-82-90732-09-2.
- 2004. Legemidler i behandling av kreftsykdommer. L2, pages 713-748. In:
- 2004. Norsk legemiddelhåndbok for helsepersonell 2004. 1766 pages. ISBN: 82-90732-08-2.
- 2004. Legemidler i behandlingen av kreftsykdommer. L2, pages 713-748. In:
- 2004. Norsk legemiddelhåndbok for helsepersonell 2004. 1766 pages. ISBN: 82-90732-08-2.
- 2004. Kreftsykdommer. T2 Kreftsykdommer, pages 93-113. In:
- 2004. Norsk legemiddelhåndbok for helsepersonell 2004. 1766 pages. ISBN: 82-90732-08-2.
- 2004. Kreftsykdommer. T2, pages 93-113. In:
- 2004. Norsk legemiddelhåndbok for helsepersonell 2004. 1766 pages. ISBN: 82-90732-08-2.
- 2001. Høyvoltanlegget ved Haukeland Sykehus. 205-220. In:
- 2001. Haukeland Sykehus. En medisinsk hjørnestein siden 1912. ISBN: 82-514-0624-2.
- 2001. Hyperthermia. 511-525. In:
- 2001. Oxford Textbook of Oncology. Second Edition. Oxford University Press. ISBN: 0-19-2629263.
More information in national current research information system (CRIStin)